Goldman Sachs’s Acrivon Therapeutics ACRV Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $167K | Buy |
140,055
+82,536
| +143% | +$98.2K | ﹤0.01% | 4776 |
|
|
2025
Q1 | $117K | Sell |
57,519
-180,033
| -76% | -$365K | ﹤0.01% | 4792 |
|
|
2024
Q4 | $1.43M | Buy |
237,552
+39,384
| +20% | +$237K | ﹤0.01% | 3704 |
|
|
2024
Q3 | $1.39M | Buy |
198,168
+173,784
| +713% | +$1.22M | ﹤0.01% | 3577 |
|
|
2024
Q2 | $141K | Buy |
+24,384
| New | +$141K | ﹤0.01% | 4443 |
|
|
2023
Q2 | – | Sell |
-13,718
| Closed | -$174K | – | 4926 |
|
|
2023
Q1 | $174K | Sell |
13,718
-25,082
| -65% | -$318K | ﹤0.01% | 4560 |
|
|
2022
Q4 | $447K | Buy |
+38,800
| New | +$447K | ﹤0.01% | 4155 |
|